1 – 11 of 11
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Reduced Intensity transplantation vs chemotherapy in CR1. A prospective, pseudorandomized study in 50–70 year old AML patients
(
- Contribution to journal › Article
- 2017
-
Mark
Androgens in women after allogeneic hematopoietic cell transplantation : Impact of chronic GvHD and glucocorticoid therapy
(
- Contribution to journal › Article
- 2016
-
Mark
Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia.
(
- Contribution to journal › Article
- 2015
-
Mark
Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.
(
- Contribution to journal › Article
- 2010
-
Mark
R CHOEP 14 x 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2-3 Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18-65 Years
(
- Contribution to journal › Published meeting abstract
-
Mark
Favorable Outcome In ALK Negative Anaplastic Large Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT) a Prospective Study by the Nordic Lymphoma Group (NLG T 01)
(
- Contribution to journal › Published meeting abstract
-
Mark
Intensive Induction Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) In Patients with Enteropathy Associated T Cell Lymphoma a Prospective Study by the Nordic Lymphoma Group (NLG T 01)
(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral t-cell lymphomas (PTCLS) - overall and subtype-specific results of a phase II study from the nordic lymphoma group
2009) 14th Annual Meeting of the European-Hematology-Association In Haematologica-The Hematology Journal 94. p.1082-1082(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2-3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18-64 Years.
(
- Contribution to journal › Published meeting abstract
- 2004
-
Mark
Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma-a Nordic Lymphoma Group study.
(
- Contribution to journal › Article
- 2003
-
Mark
CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial
(
- Contribution to journal › Article